ARTICLE | Financial News

Atox Bio raises $30M series F

December 8, 2017 4:17 AM UTC

On Dec. 4, Atox Bio Ltd. (Ness Ziona, Israel) raised $30 million in a series F round led by new investor Arix Bioscience plc (LSE:ARIX), which contributed $8 million. Fellow new investors Adams Street Partners and Asahi Kasei Corp. (Tokyo:3407) also participated, as did existing investors SR One, OrbiMed, Lundbeckfonden Ventures, Becker and Integra Holdings.

Next year, Atox plans to start a Phase II trial of lead product reltecimod (AB103) to treat acute kidney injury. The short peptide that modulates CD28 is also in the Phase III ACCUTE trial to treat necrotizing soft tissue infections. CEO Dan Teleman told BioCentury that Atox expects data from both trials in 2019...

BCIQ Company Profiles

Atox Bio Ltd.

BCIQ Target Profiles

CD28 receptor